A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

This study is testing a combination of two drugs — SHR-A2102 (a targeted antibody-drug) and adebrelimab (an immunotherapy) — with or without additional cancer treatments, for people with advanced or metastatic non-small cell lung cancer (NSCLC). It aims to find the right dose and see how well the combination works. **You may be eligible if...** - You are 18 to 70 years old - You have been confirmed by biopsy or cytology to have locally advanced or metastatic NSCLC that cannot be surgically removed - You have at least one measurable tumor lesion - Your physical performance is good (ECOG 0-1) - Your expected survival is at least 12 weeks - You have adequate organ function **You may NOT be eligible if...** - You have active or symptomatic brain metastases - You have another active cancer diagnosis - You have had serious prior reactions to immunotherapy drugs - You are pregnant or breastfeeding - You have severe autoimmune disease requiring treatment Talk to your doctor to see if this trial is right for you.